207 related articles for article (PubMed ID: 38082131)
1. How CRISPR gene editing could help treat Alzheimer's.
Thompson T
Nature; 2024 Jan; 625(7993):13-14. PubMed ID: 38082131
[No Abstract] [Full Text] [Related]
2. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
3. Applications of CRISPR-Cas9 in Alzheimer's Disease and Related Disorders.
De Plano LM; Calabrese G; Conoci S; Guglielmino SPP; Oddo S; Caccamo A
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955847
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
[TBL] [Abstract][Full Text] [Related]
5. In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease.
Park H; Oh J; Shim G; Cho B; Chang Y; Kim S; Baek S; Kim H; Shin J; Choi H; Yoo J; Kim J; Jun W; Lee M; Lengner CJ; Oh YK; Kim J
Nat Neurosci; 2019 Apr; 22(4):524-528. PubMed ID: 30858603
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-mediated genome editing: From basic research to translational medicine.
Jacinto FV; Link W; Ferreira BI
J Cell Mol Med; 2020 Apr; 24(7):3766-3778. PubMed ID: 32096600
[TBL] [Abstract][Full Text] [Related]
7. Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy.
Sarkar E; Khan A
Cancer Treat Res Commun; 2021; 27():100289. PubMed ID: 33667951
[TBL] [Abstract][Full Text] [Related]
8. Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders.
Raikwar SP; Kikkeri NS; Sakuru R; Saeed D; Zahoor H; Premkumar K; Mentor S; Thangavel R; Dubova I; Ahmed ME; Selvakumar GP; Kempuraj D; Zaheer S; Iyer SS; Zaheer A
J Neuroimmune Pharmacol; 2019 Dec; 14(4):608-641. PubMed ID: 31011884
[TBL] [Abstract][Full Text] [Related]
9. Gene editing based hearing impairment research and therapeutics.
Kang W; Sun Z; Zhao X; Wang X; Tao Y; Wu H
Neurosci Lett; 2019 Sep; 709():134326. PubMed ID: 31195050
[TBL] [Abstract][Full Text] [Related]
10. Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment.
Jiang C; Meng L; Yang B; Luo X
Clin Genet; 2020 Jan; 97(1):73-88. PubMed ID: 31231788
[TBL] [Abstract][Full Text] [Related]
11. [CRISPR-Cas9 for muscle dystrophies].
Ballouhey O; Bartoli M; Levy N
Med Sci (Paris); 2020 Apr; 36(4):358-366. PubMed ID: 32356712
[TBL] [Abstract][Full Text] [Related]
12. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
[TBL] [Abstract][Full Text] [Related]
13. [The CRISPR-Cas system: beyond genome editing].
Croteau FR; Rousseau GM; Moineau S
Med Sci (Paris); 2018 Oct; 34(10):813-819. PubMed ID: 30451675
[TBL] [Abstract][Full Text] [Related]
14. Applying gene-editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer's disease.
Schrauben M; Dempster E; Lunnon K
Brain Pathol; 2020 Sep; 30(5):992-1004. PubMed ID: 32654206
[TBL] [Abstract][Full Text] [Related]
15. CRISPR: History and perspectives to the future.
Kozovska Z; Rajcaniova S; Munteanu P; Dzacovska S; Demkova L
Biomed Pharmacother; 2021 Sep; 141():111917. PubMed ID: 34328110
[TBL] [Abstract][Full Text] [Related]
16. Applying switchable Cas9 variants to in vivo gene editing for therapeutic applications.
Mills EM; Barlow VL; Luk LYP; Tsai YH
Cell Biol Toxicol; 2020 Feb; 36(1):17-29. PubMed ID: 31418127
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9 Gene Editing: From Basic Mechanisms to Improved Strategies for Enhanced Genome Engineering In Vivo.
Salsman J; Masson JY; Orthwein A; Dellaire G
Curr Gene Ther; 2017; 17(4):263-274. PubMed ID: 29173169
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 in Alzheimer's disease: Therapeutic trends, modalities, and challenges.
Chacko L; Chaudhary A; Singh B; Dewanjee S; Kandimalla R
Drug Discov Today; 2023 Aug; 28(8):103652. PubMed ID: 37290639
[TBL] [Abstract][Full Text] [Related]
19. Development and application of CRISPR/Cas9 technologies in genomic editing.
Zhang C; Quan R; Wang J
Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
[TBL] [Abstract][Full Text] [Related]
20. A CRISPR edit for heart disease.
King A
Nature; 2018 Mar; 555(7695):S23-S25. PubMed ID: 29517035
[No Abstract] [Full Text] [Related]
[Next] [New Search]
